The Cancer Drug Development Forum organized a live webinar on the topic of Measurable Residual Disease in Acute Myeloid Leukemia on Thursday 24 February 2022 at 17:00 (CET). This webinar was composed of a 25-minute lecture given by Dr. Christopher Hourigan followed by a 30-minute discussion session.
Measurable residual disease (MRD) in adult patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT) has been identified as an important prognostic factor. Recent evidence demonstrates that intervention on high-risk patients testing positive may be able to reduce relapse and improve survival. Discrepancies between AML MRD detected by flow cytometry and molecular/genomic testing are possible, as illustrated by patient-personalized whole-genome-informed single-cell DNA and antibody-oligonucleotide sequencing. Finally, remaining questions regarding the clinical utility of AML MRD in alloHCT will lead to proposals for future clinical protocols.
- Presentation slides – not available
- Webinar recording